Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. We note that Vera Therapeutics, Inc. (NASDAQ:VERA) does have debt on its balance sheet. But the real question is whether this debt is making the company risky.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Why Does Debt Bring Risk?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first step when considering a company's debt levels is to consider its cash and debt together.

What Is Vera Therapeutics's Net Debt?

The chart below, which you can click on for greater detail, shows that Vera Therapeutics had US$50.9m in debt in March 2025; about the same as the year before. But it also has US$589.8m in cash to offset that, meaning it has US$538.9m net cash.

How Healthy Is Vera Therapeutics' Balance Sheet?

According to the last reported balance sheet, Vera Therapeutics had liabilities of US$21.9m due within 12 months, and liabilities of US$53.3m due beyond 12 months. On the other hand, it had cash of US$589.8m and US$3.59m worth of receivables due within a year. So it can boast US$518.3m more liquid assets than total liabilities.

This excess liquidity is a great indication that Vera Therapeutics' balance sheet is almost as strong as Fort Knox. On this view, lenders should feel as safe as the beloved of a black-belt karate master. Simply put, the fact that Vera Therapeutics has more cash than debt is arguably a good indication that it can manage its debt safely. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Vera Therapeutics's ability to maintain a healthy balance sheet going forward. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

See our latest analysis for Vera Therapeutics

Given its lack of meaningful operating revenue, Vera Therapeutics shareholders no doubt hope it can fund itself until it has a profitable product.

So How Risky Is Vera Therapeutics?

We have no doubt that loss making companies are, in general, riskier than profitable ones. And in the last year Vera Therapeutics had an earnings before interest and tax (EBIT) loss, truth be told. Indeed, in that time it burnt through US$156m of cash and made a loss of US$175m. While this does make the company a bit risky, it's important to remember it has net cash of US$538.9m. That means it could keep spending at its current rate for more than two years. Even though its balance sheet seems sufficiently liquid, debt always makes us a little nervous if a company doesn't produce free cash flow regularly. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. To that end, you should learn about the 4 warning signs we've spotted with Vera Therapeutics (including 2 which are a bit unpleasant) .

At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.